From DCAT Value Chain Insights (VCI)
Catalent has appointed Kevin Hambly as vice president, business development and licensing of Catelant Biologics. Mr. Hambly will be responsible for leading business development activities around Catalent’s proprietary SMARTag bioconjugation platform, as well as further developing and commercializing Catalent Biologics’ portfolio of proprietary technologies.
Most recently, Mr. Hambly served as director of business development at Seattle Genetics for nine years, where he was responsible for leading out-licensing activities for the company’s antibody drug conjugate technology and negotiating collaboration agreements.
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription